EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE
In 127 patients with atrial fibrillation (AF), the efficacy and safety of anticoagulant treatment for 12 months was studied. The mean age of patients was 69.9 ± 1.2 years, 41.7% were older than 75 years, and 20% had GFR <40 ml / min / 1.73 m2. The average CHA2DS2-VASc was 4.0, the average HAS- BL...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
The Publishing House Medicine and Enlightenment
2019-10-01
|
| Series: | Медицина в Кузбассе |
| Subjects: | |
| Online Access: | http://mednauki.ru/index.php/MK/article/view/367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411135650922496 |
|---|---|
| author | Николай Андреевич Бичан Наталья Александровна Трофименко Дарья Дмитриевна Золотарева Марина Владимировна Поцелуева Ирина Юрьевна Баркова Юлия Владиславовна Ковалева Ольга Геннадьевна Елдинова |
| author_facet | Николай Андреевич Бичан Наталья Александровна Трофименко Дарья Дмитриевна Золотарева Марина Владимировна Поцелуева Ирина Юрьевна Баркова Юлия Владиславовна Ковалева Ольга Геннадьевна Елдинова |
| author_sort | Николай Андреевич Бичан |
| collection | DOAJ |
| description | In 127 patients with atrial fibrillation (AF), the efficacy and safety of anticoagulant treatment for 12 months was studied. The mean age of patients was 69.9 ± 1.2 years, 41.7% were older than 75 years, and 20% had GFR <40 ml / min / 1.73 m2. The average CHA2DS2-VASc was 4.0, the average HAS- BLED is 1.8. 24 patients took dabigatran (Pradaхa) at a dose of 110-150 mg 2 times a day, 25 - apixaban (Eliquis) at a dose of 2.5-5 mg 2 times a day, 39 - rivaroxaban (Xarеlto) 20 mg per day and 39 - warfarin dose ensuring the maintenance of INR at the level of 1.8-2.5. It is proved that all three PLA are effective in preventing strokes with non-valvular AF in comparison with warfarin. The HR of stroke development in comparison with warfarin for dabigatran was 0.54, for apixaban – 0.41 and for rivaroxaban – 0.37. The risk of bleeding for dabigatran D 0.25, for apixaban – 0.04, for rivaroxaban – 0.18. Low risk of bleeding was associated with taking apaxaban at a dose of 2,5 mg 2 times a day and pradaxa 110 mg 2 times a day in individuals ≤ 75 years and/or having GFR<40 ml/min/1,73m2. Logistic regression revealed that the most significant factors for stroke development were age over 75 years, GFR below 40 ml/min/1,73m2 and the presence of previous strokes in history. For the risk of bleeding, significant risk factors were age over 75 years and GFR <40 ml/min/1,73m2. |
| format | Article |
| id | doaj-art-94373eda45da48cb847fa0044d0d0551 |
| institution | Kabale University |
| issn | 1819-0901 |
| language | Russian |
| publishDate | 2019-10-01 |
| publisher | The Publishing House Medicine and Enlightenment |
| record_format | Article |
| series | Медицина в Кузбассе |
| spelling | doaj-art-94373eda45da48cb847fa0044d0d05512025-08-20T03:34:52ZrusThe Publishing House Medicine and EnlightenmentМедицина в Кузбассе1819-09012019-10-011833640327EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICEНиколай Андреевич Бичан0Наталья Александровна Трофименко1Дарья Дмитриевна Золотарева2Марина Владимировна Поцелуева3Ирина Юрьевна Баркова4Юлия Владиславовна Ковалева5Ольга Геннадьевна Елдинова6НГИУВ – филиал ФГБОУ ДПО РМАНПО Минздрава России; ГАУЗ КО НГКБ № 1, г. НовокузнецкГАУЗ КО НГКБ № 1, г. НовокузнецкГАУЗ КО НГКБ № 1, г. НовокузнецкГАУЗ КО НГКБ № 1, г. НовокузнецкГАУЗ КО НГКБ № 1, г. НовокузнецкГАУЗ КО НГКБ № 1, г. НовокузнецкГАУЗ КО НГКБ № 1, г. НовокузнецкIn 127 patients with atrial fibrillation (AF), the efficacy and safety of anticoagulant treatment for 12 months was studied. The mean age of patients was 69.9 ± 1.2 years, 41.7% were older than 75 years, and 20% had GFR <40 ml / min / 1.73 m2. The average CHA2DS2-VASc was 4.0, the average HAS- BLED is 1.8. 24 patients took dabigatran (Pradaхa) at a dose of 110-150 mg 2 times a day, 25 - apixaban (Eliquis) at a dose of 2.5-5 mg 2 times a day, 39 - rivaroxaban (Xarеlto) 20 mg per day and 39 - warfarin dose ensuring the maintenance of INR at the level of 1.8-2.5. It is proved that all three PLA are effective in preventing strokes with non-valvular AF in comparison with warfarin. The HR of stroke development in comparison with warfarin for dabigatran was 0.54, for apixaban – 0.41 and for rivaroxaban – 0.37. The risk of bleeding for dabigatran D 0.25, for apixaban – 0.04, for rivaroxaban – 0.18. Low risk of bleeding was associated with taking apaxaban at a dose of 2,5 mg 2 times a day and pradaxa 110 mg 2 times a day in individuals ≤ 75 years and/or having GFR<40 ml/min/1,73m2. Logistic regression revealed that the most significant factors for stroke development were age over 75 years, GFR below 40 ml/min/1,73m2 and the presence of previous strokes in history. For the risk of bleeding, significant risk factors were age over 75 years and GFR <40 ml/min/1,73m2.http://mednauki.ru/index.php/MK/article/view/367фибрилляция предсердийдабигатранапискабанривароксабанварфаринишемический инсульткровотечения |
| spellingShingle | Николай Андреевич Бичан Наталья Александровна Трофименко Дарья Дмитриевна Золотарева Марина Владимировна Поцелуева Ирина Юрьевна Баркова Юлия Владиславовна Ковалева Ольга Геннадьевна Елдинова EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE Медицина в Кузбассе фибрилляция предсердий дабигатран апискабан ривароксабан варфарин ишемический инсульт кровотечения |
| title | EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE |
| title_full | EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE |
| title_fullStr | EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE |
| title_full_unstemmed | EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE |
| title_short | EFFICACY AND SAFETY OF ANTI-COGULAR TREATMENT IN PATIENTS WITH FIBRILLATION OF ATRIAL IN REAL CLINICAL PRACTICE |
| title_sort | efficacy and safety of anti cogular treatment in patients with fibrillation of atrial in real clinical practice |
| topic | фибрилляция предсердий дабигатран апискабан ривароксабан варфарин ишемический инсульт кровотечения |
| url | http://mednauki.ru/index.php/MK/article/view/367 |
| work_keys_str_mv | AT nikolajandreevičbičan efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice AT natalʹâaleksandrovnatrofimenko efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice AT darʹâdmitrievnazolotareva efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice AT marinavladimirovnapocelueva efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice AT irinaûrʹevnabarkova efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice AT ûliâvladislavovnakovaleva efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice AT olʹgagennadʹevnaeldinova efficacyandsafetyofanticogulartreatmentinpatientswithfibrillationofatrialinrealclinicalpractice |